Current Oncology Reports

, 16:413 | Cite as

Squamous Carcinoma of the Ovary

  • Patricia RoxburghEmail author
  • Rosalind Glasspool
Gynecologic Cancers (NS Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers


Squamous ovarian cancer (SOC) represents a (very) rare subtype of ovarian cancer. The lack of evidence on which to base management presents significant challenges. The small number of patients prohibits randomised studies to establish level 1 evidence, and no non-randomised studies or prospective series have been reported. Here, we present a review of the available literature on squamous ovarian cancer and explore some lessons learnt from squamous cancers originating from other primary sites to see if these can be applied to SOC.


Squamous Ovary Cancer Mature cystic teratoma 


Compliance with Ethics Guidelines

Conflict of Interest

Dr. Patricia Roxburgh has received grant money from Roche for a Phase I/II Study of R05503781 and from the Academy of Medical Sciences for a pre-clinical study investigating the relationship between p53 mutations and inflammation in ovarian cancer.

Dr. Rosalind Glasspool has received grant money from Boehringer Ingelheim for a trial of Nintedanib in clear cell ovarian cancer, from Roche for a trial in women with relapsed epithelial ovarian cancer and from Lilly for a trial in platinum resistant ovarian cancer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.Google Scholar
  3. 3.
    Hackethal A, Brueggmann AD, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008;9(12):1173–80.Google Scholar
  4. 4.
    Pins MR, Young RH, Daly WJ, et al. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol. 1996;20(7):823–33.Google Scholar
  5. 5.
    AciÈn P, Abad M, Mayol MJ, et al. Primary squamous cell carcinoma of the ovary associated with endometriosis. Int J Gynaecol Obstet. 2010;108(1):16–20.Google Scholar
  6. 6.
    Hasegawa E, Nishi H, Terauchi F, et al. A case of squamous cell carcinoma arising from endometriosis of the ovary. Eur J Gynaecol Oncol. 2011;32(5):554–6.Google Scholar
  7. 7.
    Mahe E, Sur M. Squamous lesions of the ovary. Arch Pathol Lab Med. 2011;135(12):1611–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Mills SE, Carter D, Greenson JK, et al. Sternberg's diagnostic surgical pathology. In: Clement PB, Young RH, editors. Ovarian surface epithelial-stromal tumours, vol. 1. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2010.Google Scholar
  9. 9.
    Chen RJ, Chen KY, Chang TC, et al. Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary. J Formos Med Assoc. 2008;107(11):857–68.Google Scholar
  10. 10.
    Dos Santos L, Mok E, Iasonos A, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol. 2007;105(2):321–4.Google Scholar
  11. 11.
    Tseng CJ, Chou HH, Huang KG, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol. 1996;63(3):364–70.Google Scholar
  12. 12.
    Ribeiro G, Hughesdon P, Wiltshaw E. Squamous carcinoma arising in dermoid cysts and associated with hypercalcemia: a clinicopathologic study of six cases. Gynecol Oncol. 1988;29(2):222–30.Google Scholar
  13. 13.
    Ayhan A, Tuncer ZS, Bilgin F, et al. Squamous cell carcinoma arising in dermoid cyst. Eur J Gynaecol Oncol. 1996;17(2):144–7.Google Scholar
  14. 14.
    Stamp GW, McConnell EM. Malignancy arising in cystic ovarian teratomas. A report of 24 cases. Br J Obstet Gynaecol. 1983;90(7):671–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Amerigo J, Nogales FF Jr, Fernandez-Sanz J, et al. Squamous cell neoplasms arising from ovarian benign cystic teratoma. Gynecol Oncol. 1979;8(3):277–83.Google Scholar
  16. 16.
    Hirakawa T, Tsuneyoshi M, Enjoji M. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathol. 1989;13(5):397–405.PubMedCrossRefGoogle Scholar
  17. 17.•
    Paliogiannis P, Cossu A, Capobianco G, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: report of two cases with molecular analysis. Eur J Gynaecol Oncol. 2014;35(1):72–6. This is the only existing publication describing attempts to molecularly characterize squamous ovarian cancer.Google Scholar
  18. 18.•
    Hoadley KA, Yau C, Wolf DM, et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014. This is an important recent paper describing molecular characterization across tissue of origin rather than ‘within-a-tissue’. Google Scholar
  19. 19.
    Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991;88(22):10124–8.Google Scholar
  20. 20.
    Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014;12(1):3–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Warren W, Biggs PJ, el-Baz M, et al. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. 1995;16(5):1181–9.Google Scholar
  22. 22.
    Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.Google Scholar
  23. 23.
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–44.PubMedCrossRefGoogle Scholar
  24. 24.
    El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10(1):20–5.Google Scholar
  25. 25.
    Raziuddin S, Masihuzzaman M, Shetty S, et al. Tumor necrosis factor alpha production in schistosomiasis with carcinoma of urinary bladder. J Clin Immunol. 1993;13(1):23–9.Google Scholar
  26. 26.
    Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23(5):634–46.Google Scholar
  27. 27.
    Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(7):627–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. Am J Clin Oncol. 2014;32(5s):5610.Google Scholar
  30. 30.
    Hinrichs CS, Stevanovic S, Draper L, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. Am J Clin Oncol. 2014;32(5s):3008.Google Scholar
  31. 31.
    Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.Google Scholar
  32. 32.
    Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.Google Scholar
  33. 33.
    Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43.Google Scholar
  34. 34.
    Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–44.Google Scholar
  35. 35.
    Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87(4):401–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8.Google Scholar
  37. 37.
    Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083–96.Google Scholar
  38. 38.
    Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116(13):3276–84.Google Scholar
  39. 39.
    Iwasa A, Oda Y, Kurihara S, et al. Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins. Pathol Int. 2008;58(12):757–64.Google Scholar
  40. 40.
    Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–36.Google Scholar
  41. 41.
    Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.Google Scholar
  42. 42.
    Svahn MF, Faber MT, Christensen J, et al. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2014;93(1):6–19.Google Scholar
  43. 43.
    Verguts J, Amant F, Moerman P, et al. HPV induced ovarian squamous cell carcinoma: case report and review of the literature. Arch Gynecol Obstet. 2007;276(3):285–9.Google Scholar
  44. 44.
    Fujii T, Oguni S, Kikuchi M, et al. p53 mutation in carcinomas arising in ovarian cystic teratomas. Pathol Int. 1995;45(9):649–54.Google Scholar
  45. 45.
    Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719–29.Google Scholar
  46. 46.•
    Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–43. This is a recent publication demonstrating that modern sequencing of even small numbers of a rare tumour type can be effective in identifying high frequency mutations.Google Scholar
  47. 47.
    Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.Google Scholar
  48. 48.
    Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120(8):1187–93.Google Scholar
  49. 49.
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787–99.PubMedCrossRefGoogle Scholar
  50. 50.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.Google Scholar
  51. 51.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.Google Scholar
  52. 52.
    Egloff AM, Lee JW, Langer C, et al., Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clin Cancer Res, 2014Google Scholar
  53. 53.
    Ford TC, Timmins PF. Successful treatment of metastatic squamous cell carcinoma of the ovary arising within a mature cystic teratoma. Clinical Ovarian Cancer. 2011;4(1):44–6.CrossRefGoogle Scholar
  54. 54.
    Rasila KK, Burger RA, Smith H, et al. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer. 2005;15(5):710–26.Google Scholar
  55. 55.
    Jackson MW, Rusthoven CG, Fisher CM, et al. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther. 2014;7:751–9.Google Scholar
  56. 56.
    Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.Google Scholar
  57. 57.
    Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29(9):1140–5.Google Scholar
  58. 58.
    Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24(1):220–5.Google Scholar
  59. 59.
    Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys. 2004;58(3):914–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Institute of Cancer SciencesUniversity of GlasgowGlasgowUK
  2. 2.The Beatson West of Scotland Cancer CentreGlasgowUK

Personalised recommendations